120 related articles for article (PubMed ID: 21317741)
21. Phase I trials of pemetrexed.
Fossella FV; Gatzemeier U
Semin Oncol; 2002 Apr; 29(2 Suppl 5):8-16. PubMed ID: 12023787
[TBL] [Abstract][Full Text] [Related]
22. [Study of use of pemetrexed in non-small cell lung cancer].
Villanueva-Herraiz S; Ortega-García MP; Camps-Herrero C; Blasco-Segura P
Farm Hosp; 2010; 34(4):194-203. PubMed ID: 20594885
[TBL] [Abstract][Full Text] [Related]
23. Interstitial pneumonitis after treatment with pemetrexed: a rare event?
Hochstrasser A; Benz G; Joerger M; Templeton A; Brutsche M; Früh M
Chemotherapy; 2012; 58(1):84-8. PubMed ID: 22377772
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.
Patel JD; Hensing TA; Rademaker A; Hart EM; Blum MG; Milton DT; Bonomi PD
J Clin Oncol; 2009 Jul; 27(20):3284-9. PubMed ID: 19433684
[TBL] [Abstract][Full Text] [Related]
25. Immune hemolytic anemia after treatment with pemetrexed for lung cancer.
Park GM; Han KS; Chang YH; Kim CH; Lee JC
J Thorac Oncol; 2008 Feb; 3(2):196-7. PubMed ID: 18303446
[No Abstract] [Full Text] [Related]
26. A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.
Kotsakis A; Agelaki S; Vardakis N; Stathopoulos G; Vamvakas L; Kalykaki A; Kentepozidis N; Kontopodis E; Sfakiotaki G; Mavroudis D; Georgoulias V
Cancer Chemother Pharmacol; 2011 Aug; 68(2):415-22. PubMed ID: 21069335
[TBL] [Abstract][Full Text] [Related]
27. Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer.
Schiller JH; von Pawel J; Schütt P; Ansari RH; Thomas M; Saleh M; McCroskey RD; Pfeifer W; Marsland TA; Kloecker GH; Sebastian M; Pirker R; Kurek R; Beadman C; Socinski MA
J Thorac Oncol; 2010 Dec; 5(12):1977-85. PubMed ID: 20978446
[TBL] [Abstract][Full Text] [Related]
28. Major and prolonged response to pemetrexed in two cases of lung adenocarcinoma with bronchioloalveolar carcinoma features.
Duruisseaux M; Cadranel J; Biron E; Pérol M; Guérin JC; Arpin D
Lung Cancer; 2009 Sep; 65(3):385-7. PubMed ID: 19346028
[TBL] [Abstract][Full Text] [Related]
29. Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis.
Pujol JL; Paul S; Chouaki N; Peterson P; Moore P; Berry DA; Salzberg M
J Thorac Oncol; 2007 May; 2(5):397-401. PubMed ID: 17473654
[TBL] [Abstract][Full Text] [Related]
30. A phase II study of pemetrexed in patients with previously heavily treated non-squamous non-small cell lung cancer (HANSHIN Oncology Group 001).
Hattori Y; Satouchi M; Katakami N; Fujita S; Kaji R; Hata A; Urata Y; Shimada T; Uchida J; Tomii K; Morita S; Negoro S
Cancer Chemother Pharmacol; 2014 Jan; 73(1):17-23. PubMed ID: 24141372
[TBL] [Abstract][Full Text] [Related]
31. Phase I study of pemetrexed and cisplatin with concurrent high-dose thoracic radiation after induction chemotherapy in patients with unresectable locally advanced non-small cell lung cancer.
Mornex F; Peignaux K; Germain T; Wautot V; Chouaki N; Bourayou N; Tourani JM
Lung Cancer; 2013 Apr; 80(1):68-74. PubMed ID: 23332163
[TBL] [Abstract][Full Text] [Related]
32. Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation.
Davies AM; Ho C; Beckett L; Lau D; Scudder SA; Lara PN; Perkins N; Gandara DR
J Thorac Oncol; 2009 Jul; 4(7):862-8. PubMed ID: 19494788
[TBL] [Abstract][Full Text] [Related]
33. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group.
Shepherd FA; Dancey J; Arnold A; Neville A; Rusthoven J; Johnson RD; Fisher B; Eisenhauer E
Cancer; 2001 Aug; 92(3):595-600. PubMed ID: 11505404
[TBL] [Abstract][Full Text] [Related]
34. Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): preliminary results of a phase II study.
Xu Y; Ma S; Ji Y; Sun X; Jiang H; Chen J; Du X; Zheng Y; Qiu G
Lung Cancer; 2011 Jun; 72(3):327-32. PubMed ID: 21056507
[TBL] [Abstract][Full Text] [Related]
35. Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): a phase II trial.
Gervais R; Robinet G; Clément-Duchêne C; Denis F; El Kouri C; Martin P; Chouaki N; Bourayou N; Morère JF
Lung Cancer; 2013 May; 80(2):185-90. PubMed ID: 23434351
[TBL] [Abstract][Full Text] [Related]
36. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2.
Zukin M; Barrios CH; Pereira JR; Ribeiro Rde A; Beato CA; do Nascimento YN; Murad A; Franke FA; Precivale M; Araujo LH; Baldotto CS; Vieira FM; Small IA; Ferreira CG; Lilenbaum RC
J Clin Oncol; 2013 Aug; 31(23):2849-53. PubMed ID: 23775961
[TBL] [Abstract][Full Text] [Related]
37. [Efficacy and toxicity of pemetrexed monotherapy for previously untreated elderly patients with non-squamous cell lung cancer with wild-type(or unknown)EGFR status].
Inomata M; Hayashi R; Tokui K; Okazawa S; Taka C; Kambara K; Suzuki K; Yamada T; Miwa T; Matsui S; Kashii T; Tobe K
Gan To Kagaku Ryoho; 2014 Jul; 41(7):849-52. PubMed ID: 25131870
[TBL] [Abstract][Full Text] [Related]
38. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group.
Rusthoven JJ; Eisenhauer E; Butts C; Gregg R; Dancey J; Fisher B; Iglesias J
J Clin Oncol; 1999 Apr; 17(4):1194. PubMed ID: 10561178
[TBL] [Abstract][Full Text] [Related]
39. [Severe cutaneous toxicity after Pemetrexed as second line treatment for a refractory non small cell lung cancer].
Tummino C; Barlesi F; Tchouhadjian C; Tasei AM; Gaudy-Marqueste C; Richard MA; Astoul P
Rev Mal Respir; 2007 May; 24(5):635-8. PubMed ID: 17519817
[TBL] [Abstract][Full Text] [Related]
40. Pemetrexed in thoracic cancer.
Goeminne H; van Meerbeeck JP
Expert Opin Pharmacother; 2006 May; 7(7):917-28. PubMed ID: 16634714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
